Biotech Values

[genisi]

Daiichi is also preparing for its exclusive U.S. launch of a generic version of Pfizer Inc.'s cholesterol drug, Lipitor, which loses patent protection in November. [Maybe not—see #msg-61160916.]

Even if Mylan's complaint is dismissed by the court, and Ranbaxy receives FDA approval on time to secure contracts, perhaps costumers will still prefer Watson's AG considering Ranbaxy's issues with the FDA (adulterated or misbranded medicine and two manufacturing units blacklisted).